×

Method to Treat Cancer with Engineered T-Cells

  • US 20190134091A1
  • Filed: 06/12/2016
  • Published: 05/09/2019
  • Est. Priority Date: 06/12/2015
  • Status: Active Grant
First Claim
Patent Images

1. An adoptive immunotherapy composition comprising an autologous T-cell population transduced with one or more lentiviral vectors encoding single or multiple chimeric antigen receptors (CARs), wherein the T cells are co-cultured with autologous antigen presentation cells transduced with one or more lentiviral vectors expressing patient-derived tumor antigens thereby generating an active patient-specific autologous anti-tumor T-cell population capable of promoting in vivo expansion, persistence of patient-specific anti-tumor T-cells resulting in tumor stabilization, reduction, and/or elimination, and/or remission and/or elimination of cancer in a patient-specific manner.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×